Top Life Sciences Startups in 2027

We push the boundaries of molecular diagnostics through quantitative technologies. BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patent-pending QCT molecular counter platform is the only technology platform that can accurately count the DNA molecules to the single-count level.

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent diseases. If you crave challenges, understudied problems, and the chance to see your work impact the millions of lives touched by cancer, there’s no better place to be. We are committed to our core values of empathy, integrity, and trust enable us to push through challenges, learn from mistakes, and support one another to reach our fullest potential. By applying advanced ML techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238M from investors such as RA Capital, Polaris Partners, Perceptive Advisors, a16z, funds/accounts advised by T. Rowe Price Associates, Inc., GV (fka Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, & Verily Life Sciences.

Force works with surgeons and their Care Teams to seamlessly support their patient’s journey. This unique approach combines a clinical voice with accessible technology, interactive, video-based education and patient-provider communication built upon each organization’s existing workflow. Our digital tools are used by patients in the home, engaging them in a daily, personalized care plan that drives successful recovery. Real-time data and outcomes are actively collected as patients move through their care, providing surgeon teams unprecedented insights into progress and performance outside the hospital. Force’s high level of patient engagement and outcomes are the result of 5 years of continuous improvement in every type of care setting with tens of thousands of users.

Alto is a telehealth pharmacy focused on helping people live healthier by making the prescription experience easier, more supportive, and more affordable. We’re transforming a $500 billion industry by reinventing what a pharmacy can do, for both patients and providers—from hand-delivering medications for free to offering on-call help by text or chat. Over one million deliveries, over a thousand five-star Yelp reviews, and an NPS score of +86 later, we’re proud to say we’ve built a pharmacy that people truly love.

Our story started when our co-founders, whilst working as medical doctors, recognized that the holistic textbook version of medicine was not at all what was being provided for patients. The reality is that a stretched healthcare system fails to engage people in their medical care at the preventative stages. As a result, the $3 trillion currently spent on healthcare goes on to prevents only 10% of premature deaths. With digital therapeutics, we have the opportunity to prevent 40% of premature deaths that are caused by behavioral patterns. Quit Genius is a behavior change platform that combines digital coaching, personalized content, wearable technology and medication to help people overcome addictive behaviors.

Founded by a biologist and an architect, our team has exemplified the power of interdisciplinary collaboration from its beginning. We believe that sewage offers a unique opportunity to make public health more data-driven and effective and that the best technologists can improve society, not just your photo filters. We believe that building cutting-edge technology that positively impacts our world requires collaboration across many disciplines with people from all walks of life. We equally value the perspective of technical experts and community stakeholders. We believe in radical transparency both internally and with our customers. We commit to creating a data ecosystem that respects the privacy of individuals and communities.

PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with [Amgen](endpts.com/amgen-lines-up-new-ai-biotech-partner-in-postera), [Pfizer](endpts.com/a-new-ai-startup-has-emerged-and-pfizer-likes-what-it-sees) and the [NIH](endpts.com/nih-grants-over-500m-to-create-antivirals-for-future-pandemics). PostEra also launched and led the world's largest open-science drug discovery effort; [COVID Moonshot](postera.ai/moonshot).

We’re a growing company. Everything we do, we do to help people grow into the best version of themselves. As the pioneers of hair wellness, we create natural, clinically effective formulas for hair growth and provide support for people at every step of their hair journey. Our multi-factorial approach targets the root causes of hair thinning using a patented blend of medical-grade botanicals—and is recommended by over 3,000 physicians and hair professionals for trusted, reliable results. We never settle, and are continuously challenging existing treatments and methodologies to advance the frontier of hair science. As we help our customers grow, we grow too—by embracing individuality and differences, leading by example, and empowering ourselves and others with our passion for wellness and innovation. Keep growing. It’s our mantra. Our commitment to helping anybody and everybody committed to realizing their own potential to grow.

Synonym is a financing and development platform for essential biomanufacturing infrastructure - we’re building production capacity for synthetic biology companies and creating a new asset class for investors. We provide synbio companies with flexible capacity for microbial fermentation.  We build new biomanufacturing facilities, offering synbio companies access to dedicated, scalable capacity for minimal upfront capital investment. We accelerate project timelines and minimize internal complexity by handling facility development activities, from site selection through commissioning. We provide capital markets partners with curated access to biomanufacturing infrastructure investments, an emerging asset class and we manage these investments on behalf of investors, with an emphasis on risk management and maximizing returns.

One Medical is the fastest growing primary care practice in the country. But this is no ordinary doctor’s office. Everything we do is built around how people live today. From our office experience to the exceptional people we hire to technology that simplifies getting — and giving — care, we’re transforming healthcare and truly changing people’s lives.